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Abstract
The C-terminal binding protein (CtBP) is a NADH-dependent transcriptional repressor that links 
carbohydrate metabolism to epigenetic regulation by recruiting diverse histone modifying 
complexes to chromatin. Here, global profiling of CtBP in breast cancer cells reveals that it drives 
epithelial to mesenchymal transition, stem cell pathways, and genome instability. CtBP expression 
induces mesenchymal and stem cell-like features while CtBP depletion or caloric restriction 
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reverses gene repression and increases DNA repair. Multiple members of the CtBP-targeted gene 
network are selectively down-regulated in aggressive breast cancer subtypes. Differential 
expression of CtBP-targeted genes predicts poor clinical outcome in breast cancer patients, and 
elevated levels of CtBP in patient tumors predict shorter median survival. Finally, both CtBP 
promoter targeting and gene repression can be reversed by small molecule inhibition. These 
findings define broad roles for CtBP in breast cancer biology and suggest novel chromatin-based 
strategies for pharmacologic and metabolic intervention in cancer.
Introduction
Cancer evolves through a multi-step process driven by a global reprogramming of cellular 
gene expression patterns that confers adaptive advantages for tumor growth, proliferation 
and dissemination 1. This phenotypic transformation is accomplished by diverse molecular 
strategies that control programs of cellular function by directing large-scale changes in gene 
expression 2. Although our understanding of how specific genetic mutations can act as 
drivers of cancer is well established, the paradigms addressing how epigenetic changes are 
orchestrated to influence hallmarks of cellular malignancy are only just beginning to 
evolve 3. Epigenetic changes represent potentially reversible covalent modifications to 
chromatin that can be transmitted to subsequent generations in the absence of changes to 
genetic sequence. In combination with DNA methylation, and histone modifications 
(including acetylation, methylation, phosphorylation and ubiquitylation), these covalent 
modifications constitute a “histone code” that is sculpted and interpreted by an assortment of 
chromatin regulatory complexes that bind (“read”), place (“write”), and remove (“erase”) 
chromatin marks to create the living “libretto” that we now refer to as the ‘epigenome’ 3. 
How the spatial and kinetic distribution of these chromatin regulatory complexes are 
coordinated to influence the epigenome has become the focus of extensive investigation 4.
The C-terminal binding proteins (CtBP1/2) are a dimeric family of proteins encoded by two 
paralogous genes, CtBP1 and CtBP2, that play extensive roles in animal cell development 5. 
CtBP homo- and hetero-dimerize in the presence of NADH to recruit various chromatin 
modifying complexes, including histone methyl-transferases (HMTs), histone demethylases 
(HDMs), and histone deacetylases (HDACs) (e.g LSD1, HDAC1/2/4/6/7, G9a and EHMT) 
to chromatin bound sequence-specific transcription factors 5. In this way, CtBP has the 
potential to link metabolic status to specific changes in the epigenetic landscape of the 
nucleus and play a dominant role in determining cellular behavior and fate 6, 7. However, 
with the exception of a small set of tumor suppressor genes (e.g. CDH1 (E-Cadherin), 
CDKN2A (p16), Sirtuin 1 and BRCA1) 6, 8, the genome-wide targets of CtBP in the 
mammalian nucleus remain unknown.
Previously we showed that CtBP repressed the transcriptional expression of the early onset 
breast cancer gene, BRCA1, by recruiting HDAC activity to the BRCA1 promoter to 
antagonize p300 driven histone acetylation 8. In this current work we extend this observation 
by profiling the global association of CtBP with the genome of breast cancer cells by 
combining chromatin immunoprecipitation with deep sequencing (ChIP-Seq) to define 
cellular programs driven by CtBP with clinical importance, and potential for therapeutic 
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targeting. Here we reveal that CtBP plays a prominent role in epigenetic reprogramming that 
drives major hallmarks of cancer through transcriptional mechanisms that are both linked to 
metabolism and susceptible to pharmacologic intervention.
Results
CtBP targets cellular reprograming and genome stability
Recent molecular and morphological studies have shown that most breast cancers can be 
separated into distinct subtypes that segregate along the hierarchy of normal mammary 
epithelial differentiation and development and include, luminal A, luminal B, human 
epithelial growth factor receptor 2 (HER2) positive, basal-like, and claudin low 9, 10. 
Luminal A and B are well-differentiated tumors and usually estrogen receptor positive. The 
basal-like and claudin low subtypes are much more primitive and usually deficient in 
receptors for estrogen and progesterone and HER2 9, 10. This classification has substantial 
diagnostic and prognostic importance. The more primitive tumors (e.g. basal-like and 
claudin low) usually show a more aggressive behavior with worse clinical outcome 9, 10. 
Properties of these tumors include mesenchymal features associated with reactivation of 
embryonic programs that promote epithelial to mesenchymal transition (EMT), acquisition 
of stem cell-like self-renewal attributes, increased genome instability, and the production of 
cellular progenitors with the ability to seed new tumors, often referred to as “tumor initiating 
cells” (TICs) 1112, 13. Such features are recognized as important hallmarks or drivers of 
cancer 1.
We profiled the binding of CtBP across the genome of the human breast cancer cell line 
MCF-7, a well differentiated estrogen receptor positive luminal subtype, using antibodies 
that recognize epitopes common to both CtBP1 and CtBP2 (Fig. 1). Genome wide ChIP-seq 
analysis identified a total of 6607 binding sites for CtBP with a FDR<0.00001. 1823 of these 
binding sites were in promoter regions (Table 1). Consistent with the established role for 
CtBP in animal cell development 14, ontology analysis of the 1823 gene promoters 
demonstrates that CtBP interacts with gene networks that have broad roles in cellular 
homeostasis including cellular macromolecule metabolic processes, RNA processing, gene 
expression, and cellular metabolic processes (Supplementary Table S1). However, a large 
number of CtBP targeted genes belong to categories that are important in malignant tumor 
transformation and progression, including embryonic development, cellular response to 
DNA damage, cell cycle, cell proliferation, cell death, cell adhesion and chromatin 
modifications (Fig. 1a). CtBP binding sites located outside of promoter regions are also 
nearby genes that show a similar distribution of these categories (Supplementary Figs. S1a–
d). In particular, many of the CtBP target genes belong to functional gene categories that 
play major roles in driving the more aggressive mesenchymal phenotypes of basal-like and 
claudin low tumors including genome instability, EMT, and stem cell-like/tumor initiating 
cell (TIC) pathways 10, 13 (Fig. 1b). The core list of 30 CtBP bound genes in Figure 1b (10 
from each category, each with Z-scores > 30.17), include multiple genes that have been 
previously shown to play major roles in breast cancer etiology, genetic susceptibility and 
tumor progression 15, 16. It was therefore selected for use in subsequent validation studies.
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In silico analysis of consensus binding motifs centered under CtBP peaks shows a large 
enrichment of transcription factor binding sites (TFBS) for ETS, CREB, STAT and 
EGR1/SP1 families of transcription factors (Fig. 1c and Supplementary Fig. S2). Notably, 
these motifs are over-represented in the promoters of both bi-directional and DNA repair 
genes including BRCA1, PALB2, FANCD2, FANCM and RAD51C 17, 18 (also see Fig. 1b). 
In addition, the ETS-pathway has been identified as a major program in basal-like breast 
cancers 19. This finding suggests that CtBP recruitment is likely to be coordinated through a 
common promoter context to control specific cellular programs.
CtBP is often found in complexes with the histone demethylase, LSD1, where it plays a 
broad role in both repressive and activating transcriptional programs in various cell 
types 20–22. In breast epithelia, LSD1 represses invasion and metastasis 23. However, 
comparison of the targets of CtBP and LSD1 in MCF-7 and human ES cells reveals less than 
a 7% and 10% overlap, respectively (Fig. 1d). This indicates that the major functions of 
CtBP in epigenetic regulation are likely to involve complexes that are distinct from LSD1 
targeting in mammary epithelial cells.
CtBP promotes EMT and enhances tumor initiating cell traits
Though CtBP predominantly produces repression of target genes, both the dimeric state of 
CtBP and composition of the CtBP-containing complex are major determinants of whether 
CtBP will repress or induce gene expression 21, 24, 25. An analysis of the relative enrichment 
of CtBP targeted genes in molecular signatures of EMT 26 shows a significant (P=9.5 E-11) 
overlap with genes that are differentially repressed (down-regulated) compared to activated 
(up-regulated) during EMT (Fig. 2a). Similarly, CtBP bound genes are significantly more 
enriched (P=7.37E-10) in the genes that are differentially repressed in the cancer TIC/Stem 
cell signature 12 (Fig. 2a). These findings implicate a predominant role for CtBP in driving 
both EMT and stem cell-like attributes through transcriptional repression.
To obtain a general impression of the correlation between CtBP promoter occupancy and 
gene expression, microarray analysis was used to compare gene expression patterns in 
control versus MCF-7 cells that had been depleted of CtBP by RNAi (Fig. 2b). This screen 
identified 1585 genes that showed significant (P< 0.05) up-regulation and 1248 genes that 
showed down regulation by either direct or indirect CtBP influence. Using the FDR cutoff 
described above, 179 of the up-regulated and 100 of the down-regulated genes were 
identified as CtBP targets by ChIP-seq. Although the specific functional distribution of 
differentially expressed gene classes is similar to the ChIP-seq distribution shown in Figure 
1a (Supplementary Fig. S7), the modest size of the overlap is likely a reflection of direct and 
indirect influences of CtBP depletion in combination with the insensitivity and low dynamic 
range of hybridization-based array technology 27. Therefore, to generate a more accurate 
view of the relationship between CtBP occupancy and gene expression, a total of 71 genes 
(30 genes from Figure 1b and 41 additional genes collected from gene categories described 
in Figure 1; in total representing 26% of the EMT overlap and 38% of the TIC overlap in 
Figure 2a) were selected for validation by quantitative mRNA expression (qRT-PCR) and 
quantitative chromatin immunoprecipitation. Both cells depleted of CtBP by RNAi and cells 
over-expressing CtBP were analyzed and compared (Fig. 2c and Supplementary Figs. S3–
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S6). By this analysis, 56% of the validation genes showed significant (P<0.05) up-regulation 
following CtBP depletion while 14% showed down-regulation (Supplementary Figs. S4–
S6). Conversely, 46% of genes in cells over-expressing CtBP showed significant repression 
(P<0.05) while 15% showed upregulation. 100% of genes tested by quantitative ChIP 
showed a significant peak (P<0.05) and 90% (27 of 30) genes showed a significant decrease 
(P<0.05) of CtBP binding following CtBP gene depletion by RNAi (Supplementary Figs. S3 
and S6). These data show that many of the genes identified by ChIP-seq analysis are likely 
to be bona fide functional targets of CtBP.
Global depletion of CtBP increases DNA repair
CtBP bound sequences are enriched in transcription factor binding sites found in the 
promoters of genes involved in DNA repair (Fig. 1b–c). Many of these are derepressed 
following CtBP depletion (Fig. 2c and Supplementary Fig. S4). These findings, in 
combination with the previously reported repressive effects of CtBP on BRCA1 
expression 8, suggests that CtBP levels may have a strong influence on DNA repair. To test 
this, comet assays were performed on MCF-7 cells exposed to oxidative DNA damage 
before or after CtBP gene depletion by RNAi (Fig. 2d). Analysis reveals that cells depleted 
of CtBP show significantly increased DNA repair (P=6.0 E-09) compared to control cells 
(Fig. 2e). In contrast, gene depletion of BRCA1 by RNAi has the opposite effect (decreased 
DNA repair), though with lower relative significance (P=1.50 E-05) (Supplementary Fig. 
S8). These findings establish a substantial role for CtBP in governing transcriptional 
programs that control genome stability.
CtBP drives acquisition of mesenchymal traits
To assess the functional influence of CtBP on the acquisition of mesenchymal traits, we 
compared the effect of CtBP expression on the properties of two cell lines at opposite poles 
of the hierarchy of mammary differentiation (Fig. 3). MCF-7 cells serve as a representative 
of luminal differentiation while MDA-MB-231, an estrogen receptor negative and highly 
metastatic cell line, is representative of the claudin low subtype. In both cell lines CtBP 
depletion induces derepression of most of the 30 CtBP-targeted genes in Figure 1b, however 
gene depletion seems to derepress a substantially larger portion of the MDA-MB-231 cells 
than the MCF-7 (80% versus 53%) (Figs. 3a–b and Supplementary Fig S4). In contrast, 
CtBP over-expression has a more substantial influence on the repression of the 30 CtBP 
targets in MCF-7 compared to MDA-MB-231 (43% versus 6%) (Figs. 3a–b and 
Supplementary Fig S5). CtBP is associated with a variety of chromatin modifying 
complexes 5. At the BRCA1 promoter, loss of CtBP results in increased BRCA1 promoter 
acetylation and increased BRCA1 expression 8. However, in the absence of direct empirical 
information or further study of the specific forms of CtBP complexes in different cell types 
or knowledge of the differential promoter recruitment of HATs, HDACs, HMTs, and 
HDMs, it is not possible to readily predict what modifications will be altered and in what 
direction at each individual CtBP target. Regardless, CtBP gene depletion produces 
substantial changes in both H3 and H4 histone acetylation at most of the 30 CtBP gene 
targets (Fig. 3c and Supplementary Fig. S9).
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A well characterized attribute of the acquisition of mesenchymal features and EMT is 
increasing vimentin expression accompanied by decreasing E-cadherin expression 11. To 
profile the influence of CtBP on these properties, the change in the E-cadherin/Vimentin 
ratio 28 was measured (Fig. 3d). In both MCF-7 cells and MDA-MB-231 cells, CtBP gene 
depletion increased the ratio of E-cadherin/Vimentin while CtBP expression lowered it, 
consistent with the ability of CtBP to drive the mesenchymal phenotype in both 
mesenchymal and luminal cells. Furthermore, the role of CtBP in driving mesenchymal 
features is well illustrated by the ability of enforced CtBP expression to substantially 
increase MCF-7 mobility in wound healing assays (Fig. 3e).
EMT has recently been shown to activate programs that promote the acquisition of stem 
cell-like properties 11. This often occurs in progenitor cells with increases in CD44 as 
opposed to CD24 expression 11. The influence of CtBP on stem-like features of MCF-7 and 
MDA-MB-231 was measured by profiling changes in the CD44/CD24 ratio 10 following 
enforced CtBP expression or CtBP gene depletion (Fig. 3f). In both cell lines, expression of 
CtBP increased the CD44/CD24 ratio consistent with the attributes of cells with progenitor/
stem cell-like features, while CtBP depletion decreased that ratio (Fig. 3f). Thus CtBP 
appears to be able to drive the mesenchymal phenotype in mammary cells regardless of what 
position they are along the spectrum of mammary differentiation.
CtBP links cellular metabolic status to genome stability
Pharmacological manipulation of endogenous NADH levels influences BRCA1 expression 
through CtBP, with higher levels of NADH causing BRCA1 repression 8. To ask whether 
manipulation of endogenous NADH levels by carbohydrate over-loading could influence 
expression of CtBP-targets, we grew MCF-7 cells in high or “diabetic” levels of glucose 
(450 mg/dl) versus normal concentration (100 mg/dl) (Fig. 4). CtBP dimerization, nuclear 
localization, and stability are enhanced when bound to NADH 7, 29. As demonstrated by 
both immuno-histochemistry and Western blot analysis, MCF-7 cells grown in low levels of 
glucose, demonstrate decreased levels of NADH relative to NAD+, and show lower nuclear 
accumulation of CtBP in comparison to cells grown under conditions of high glucose (Figs. 
4a–c). These changes are, in turn, associated with increased nuclear levels of BRCA1 
protein, decreased levels of CtBP loading at the BRCA1 promoter, compensatory increases 
in relative histone 3 acetylation 8 (Figs. 4c–e and Supplementary Fig. S10a); and a 
significant increase in the expression of BRCA1 mRNA and other CtBP-targeted genes 
important in DNA repair (Fig. 4f and Supplementary Fig. S10b). Finally, as predicted, cells 
incubated under high glucose condition show a demonstrably reduced DNA repair capacity 
that is not due to differences in cell cycle entry (Figs. 4g–h and Supplementary Fig. S10c).
CtBP gene networks distinguish aggressive breast cancer
The embryonic properties linked to EMT, including cellular plasticity, dedifferentiation, de-
regulated cell growth, and genome instability, are common features associated with more 
aggressive molecular subtypes of breast cancer 30, 31. To ask whether CtBP-target genes 
define networks that are more associated with aggressive subtypes of breast cancer, we 
profiled the expression of CtBP target genes in publically available breast cancer patient 
gene expression data sets (Fig. 5a). Analysis by unsupervised hierarchical clustering 
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identified a large class or cluster of CtBP-targeted genes that are selectively downregulated 
in the basal-like and claudin low subtype of cancers (Fig. 5a). Moreover, ANOVA 
analysis 10 of expression of the CtBP-targeted gene categories (Fig. 1b), shows that down 
regulation of many of the genes within the EMT and Stem Cell/TIC categories significantly 
distinguish (P-values between 1.08E-11 and 1.17 E-140) basal-like and claudin low from the 
other subtypes (Fig. 5b and Supplementary Fig. S11). GRHL2 has recently been shown to 
play a dominant role in EMT by regulating cell polarity and is a strong discriminator of 
claudin low subtypes 32, 33. FOXA1 potently distinguishes basal-like and claudin low from 
the more luminal subtypes and has recently been shown to actively repress the basal-like 
phenotype 34, 35 (Figs. 1b, 5b and Supplementary Fig. S11). Similarly, gene set enrichment 
analysis (GSEA) 36 of the genes altered by CtBP RNAi depletion using micro-array analysis 
(Fig. 2b) also reveals substantial CtBP dependent participation in multiple pathways 
important in breast cancer biology (Supplementary Figs. S12a–g)37. Moreover, the clinical 
relevance of the CtBP-targeted gene list is further supported by analysis of two independent 
breast cancer gene expression studies revealing that patients, whose tumors can be classified 
as showing differential expression of CtBP-target genes, have significantly shorter 
metastasis free survival by Kaplan-Meier analysis (Fig. 5c).
High CtBP predicts poor survival in breast cancer patients
The data presented thus far suggests that CtBP is likely to play a substantial role in the 
etiology and progression of human breast cancer. To examine CtBP expression in patient 
tissues, tumor samples from two independent breast cancer cohorts were stained for CtBP 
protein expression by immuno-histochemistry using antibodies against CtBP (Fig. 6a). In 
normal breast CtBP, nuclear immuno-reactivity is generally light and non-uniform with 
many nuclei showing little or no CtBP staining, while in patients with basal-like, triple-
negative breast cancer, CtBP1 staining is much more intense (Fig. 6a). When digitally 
scored for CtBP nuclear staining to measure percent of nuclei with scores of 0–3 (nuclear 
intensity) or a score weighted by nuclear size (nuclear score), triple negative breast cancer 
shows a nuclear intensity and nuclear score that is 25 and 22 times higher than normal breast 
respectively (Fig. 6a). This system was then used to score the first patient tissue cohort (the 
training set) (Fig. 6b). When this scoring system was used to segregate patient samples into 
3 groups of low (nuclear score <100; nuclear intensity <2); medium (nuclear score 100–300; 
nuclear intensity 2–5) and high (nuclear score >300; nuclear intensity >5) CtBP score, there 
was a clear trend showing an inverse relationship between CtBP staining and patient median 
survival by Kaplan Meier analysis (Fig. 6b). Using the same parameters these trends were 
reproducible in a second independent cohort (Patient validation set) of equivalent size (Fig. 
6c). This suggests that elevated CtBP can function as a surrogate biomarker for altered 
epigenetic regulation in breast cancer patients who may progress to more advanced disease.
Reversal of CtBP function by small molecule Inhibition
CtBP is a potent epigenetic regulator that responds to cellular metabolism through its 
interaction with NADH. Therefore, pharmacological targeting of CtBP may, in principle, 
provide a means of derepressing its transcriptional targets. Though CtBP is a member of the 
d-2-hydroxyacid dehydrogenase family, its true substrate is not known 38. Recent studies 
indicate that 2-Keto-4-methylthiobutyrate (MTOB), an intermediate in the methionine 
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salvage pathway, can bind CtBP and reverse repression of the proapoptotic gene, BIK, in 
colon cancer cells 39, 40. To test if MTOB could disrupt expression of CtBP target genes in 
breast cancer, both MCF-7 and MDA-MB-231 were incubated in the presence and absence 
of MTOB and the 30 CtBP targeted genes (Fig. 1b) were screened for changes in gene 
expression (Figs. 7a–b and Supplementary Fig. S13), and promoter occupancy (Figs. 7d–e 
and Supplementary Figs. S14–S15). MTOB treatment caused significant derepression 
(P<0.05) of 40% of these genes in MCF-7 and 46% in MBA-MD-231. Approximately 3% 
and 10% of genes, respectively, were repressed (Figs. 7a–b and Supplementary Fig. 13). The 
concordance of the MTOB effect between the two cell lines was 70% (21/30) indicating that 
MTOB action is relatively independent of breast cancer subtype and epithelial programming 
(Fig. 7b and Supplementary Fig. S13). However, though it is difficult to know the extent to 
which this derepression is due to direct targeting of CtBP occupancy or to indirect effects; 
incubation with MTOB caused a significant displacement (P<0.05) of CtBP from 67% of the 
promoters in MCF-7 and only 30% from promoters in MDA-MB-231 (Fig. 7d and 
Supplementary Fig. S14). The lower MTOB-induced CtBP displacement in MDA-MB-231 
could be due to the lower level of CtBP binding found at these genes (Supplementary Fig 
S3). This could explain, in part, why the concordance between changes in CtBP occupancy 
and gene expression is significantly higher for MCF-7 (>70%) compared to MDA-MB-231 
(50%) following MTOB treatment (Figs. 7a–d and Supplementary Figs. S13–S15). 
Nonetheless, these data suggest that the predominant mode of MTOB action is through its 
eviction of CtBP from occupied promoter regions. Finally, treatment with MTOB 
antagonizes the mesenchymal phenotype (Figs. 7e–f). Addition of MTOB to both MCF-7 
and MDA-MD-231 increases the pro-epithelial E-cadherin/Vimentin ratio while reducing 
the pro-mesenchymal CD44/CD24 ratio, with a more significant trend (P<0.05) in MCF-7 
(Figs. 7e–f). Taken all together, these findings provide substantial evidence that 
pharmacological targeting of CtBP to disrupt malignant cellular reprogramming may be a 
feasible “epigenetic strategy” for therapeutic intervention.
Discussion
The evidence of a link between obesity and diabetes and increased mortality from breast 
cancer is incontrovertible 41–44. An important feature of the dysfunctional energetics 
associated with obesity and diabetes and malignant transformation, is elevated carbohydrate 
metabolism, a central component of the Warburg Effect 45, 46. This elevated level of 
carbohydrate metabolism, whether due to the over-nutrition of obesity or the Warburg Effect 
of cancer bioenergetics, results in increased levels of NADH 47–49. In this study we propose 
CtBP is a key downstream epigenetic effector of elevated NADH. Therefore through CtBP, 
changes in cellular metabolic status can drive genome-wide changes in chromatin through 
targeted recruitment of CtBP that facilitates the acquisition of epigenetically reprogrammed 
properties that promote genome instability, dedifferentiation, and the transformation to a 
more mesenchymal phenotype.
Though this study provides one of the first to profile the binding of CtBP throughout the 
mammalian genome; how, when, and where the different CtBP complexes target and 
coordinate the recruitment of specific chromatin modifiers, and their subsequent effect on 
the epigenome remain to be defined. These epigenetic networks and programs are likely to 
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differ by cellular process and cell type and are likely to reflect a hierarchy of CtBP 
complexes formed under specific cellular conditions and environments as we have seen in 
comparing the mesenchymal MDA-MB-231 cell line, with the luminal MCF-7 (Figs. 3, and 
7). This difference has been demonstrated in prior studies where loss of CtBP had a much 
great effect on mitotic fidelity in MDA-MB-231 than MCF-7 50. Future studies to correlate 
global alterations in histone and DNA modification with changes in CtBP levels (via either 
genetic or metabolic disruption) in multiple breast cancer subtypes will be necessary to 
better define the mechanism underlying these differences.
Approximately 5–10% of breast cancers are secondary to inherited mutations of cancer 
predisposing genes. It is striking that, of the known and newly identified breast cancer 
predisposing genetic mutations, a substantial number are targeted for repression by CtBP, 
including PALB2, BRIP1, RAD51C and BRCA1 16. Thus the observation that many patients 
develop breast cancers with features of inherited disease without demonstrating mutation in 
genes characteristic of the disease 51, is consistent with a role played by CtBP-regulated 
pathways in such tumors. Notably, decreased expression specifically of DNA repair proteins 
is associated with shortened time to recurrence in triple-negative breast cancer 52. This is 
consistent with the demonstration, in this current study, of the impact of CtBP targeting on 
genome stability. Nearly one third of the Fanconi Anemia complementation group is 
targeted by CtBP. Therefore, it is not surprising that loss of CtBP expression or function 
results in a significant improvement in DNA repair in breast cancer cell lines (see Figs. 1d, 
and 2d–e). Most importantly, targeting by CtBP suggests that these hereditary risk factors 
for breast cancer may be worsened by lifestyle factors influencing metabolic imbalance.
Finally, many of the new driver mutations identified by recent systematic sequencing of 
cancer genomes has uncovered several genes with functional roles in epigenetic 
regulation 53. CtBP represents a novel class of versatile, multi-potent epigenetic regulators 
that is likely to play many different roles in cancer etiology and progression. The finding 
that MTOB can act as a small molecular inhibitor that can reverse genomic targeting by 
CtBP, provides a proof of principle that pharmacological manipulation of CtBP is feasible. 
Thus epigenetic targeting through CtBP promises to be a new and exciting area of future 
therapeutic intervention. New efforts will have to be directed at finding compounds that will 
function in the nanomolar to micromolar range. Given that weight gain and obesity represent 
modifiable cancer risk factors linked to lifestyle, a better understanding of CtBP will fuel 
new ideas and creative strategies for combined behavioral and therapeutic approaches to 
cancer treatment and prevention.
Methods
Reagents
Hydrogen peroxide is from Invitrogen as 30% stock. MTOB (4-methylthio-2-oxobutyric 
Acid) is from Sigma-Aldrich and was dissolved in medium to 250mM and diluted to 10mM 
final concentration in cell culture. The antibody to CtBP used for ChIP was purchased from 
Santa Cruz Biotechnology and is cross-reactive with both CtBP1 and CtBP2. The anti-
CtBP1 specific antibody and anti-CtBP2 specific antibody were purchased from BD 
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biosciences. Anti-acetylated histone H3, anti-acetylated histone H4 antibodies and anti-
γH2AX antibody were obtained from Millipore.
Cell culture and tissues
Both MCF-7 cells and MDA-MB-231 cells were maintained in regular DMEM 
supplemented with 10% (v/v) FBS, penicillin-streptomycin (Invitrogen) and insulin. In 
addition, the regular DMEM has 4.5g/L glucose and is considered as high glucose culturing 
(HG) compare to 1.0g/L glucose DMEM medium(LG). The low glucose cultured cells were 
used for experiments only after 3 month of continuous culture in low glucose medium.
ChIP and ChIP-seq
All ChIP experiments were carried out as described 8. The detailed procedure is provided in 
the Supplementary Methods.
ChIP-seq data analysis
The detailed ChIP-seq data analysis is provided in the Supplementary Methods. Briefly, the 
36-mer short-read tags were mapped to the human genome (UCSC HG19). Enrichment of 
tags in a 250 bp target window relative to a 200 kb surrounding window (local background) 
was gauged by a model based on the binomial distribution. The hotspots are defined by a z-
score calculated using the target window and the background window signals both centered 
on the tag. In addition, ChIP hotspots were refined into 150 bp peaks using a peak-finding 
procedure. The sequencing data from matching input samples are used for the processing of 
the ChIP data, as a measure of background signal.
Motif discovery and enrichment analysis
A motif discovery analysis was performed on selected DNA sequences using MEME 54 on 
parallel clusters at the NIH Biowulf supercomputing facility. DNA sequences for MEME 
input were from the top 1500 (by tag density) hotspots among all CtBP binding hotspots. To 
limit the computational load, only the 200 bp regions with the highest tag density were used 
instead of the entire width of a hotspot in cases where the hotspot spanned greater than 200 
bp. The width of motifs to discover was set to 6 and 20 for minimum and maximum, 
respectively. To identify motifs for known transcription factor binding, individual position-
specific probability matrices against the Transfac database were queried using the TomTom 
software (http://meme.nbcr.net/meme/cgi-bin/tomtom.cgi). Statistically significant matches 
were retrieved that share the majority of specific nucleotides in the sequence motifs. To 
generate consensus read densities for positions relative to transcription start sites (TSS), the 
total number rd* of read tags summed over all Refseq annotated TSS normalized to the 
length L of the genome and the total number N of aligned reads (rd* = rd* L/N) was profiled 
such that rd*=1 approximately corresponds to an un-enriched distribution of reads.
Gene expression and Microarray analysis
The total RNA from 3 biological replicates of control MCF-7 cells and CtBP knockdown 
MCF-7 cells were prepared using the RNAeasy kit (Qiagen) following the manufacturer’s 
protocol. Synthesis of cDNA from total RNA and hybridization/scanning of microarrays 
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were performed with Affymetrix GeneChip products (HGU133plus2) as described in the 
GeneChip manual. Raw data files (.CEL) were converted into probe set values by RMA 
normalization. Following RMA-normalization, Bioconductor packages was applied in R 
statistical environment to generate a list of genes that are differentially expressed between 
control cells and CtBP knockdown cells and p<0.05 was considered as significant. The data 
was stored as NCBI GSE36529.
Comet assay
Comet assays were performed according to Olive et al 2006 55. Briefly, a single-cell 
suspension was prepared using enzyme disaggregation. The cells were exposed to neutral 
lysis buffer (2% sarkosyl, 0.5M Na2EDTA, 0.5 mg/ml proteinase K (pH 8.0); equilibrated at 
4 °C) for overnight at 37°C. Following electrophoresis the cells were stained by SYBR 
Green and the images were obtained using fluorescent microscopy. The tail moment was 
calculated by the following formula: Tail moment=tail length x percentage of Tail DNA. 
Percentage of Tail DNA= aT×iT/(aT×iT+aH×iH), where aT = the tail area, iT = average 
intensity of tail, aH = the head area and iH = average intensity of Head. Comet Score™ was 
used to analyze the comet pictures.
Immunofluorescence staining of cells
Cells were grown on cover-slips and fixed in 3.5% paraformaldehyde. For γH2AX staining 
the cells were incubated with Alexa Fluor® 488 Goat Anti-Mouse IgG for 1hr. Cells were 
irradiated at 10 Gy to induce DNA damage.
Immunohistochemistry staining of tissues
Detailed methods for immunohistochemistry is provided in the Supplementary Methods. 
Formalin-Fixed, Paraffin-Embedded (FFPE) tissues were de-paraffinized by submerging the 
slides in Xylene. Antigen retrieval was performed in buffers containing 100mL of 1mM 
EDTA pH 8.0. Staining was developed using secondary antibody conjugated with horse-
radish peroxidase (HRP) (Dako EnVision + System-HRP Labelled Polymer Anti-Rabbit or 
Anti-mouse and counterstained with hematoxylin.
Analysis of Tissue Microarrays
Immunohistochemically stained tissue slides were converted to digital slide images by 
scanning the slides on an Aperio ScanScope XT slide scanner. High resolution digital slide 
images were then archived into Aperio’s digital pathology information management system 
“Spectrum”. Digital slide images were analyzed using Aperio’s IHC Nuclear Image 
Analysis algorithm to assess the nuclear staining for CtBP in MCF7 cells and quantify the 
intensity of individual cells. Values and colors are assigned to individual cells based on the 
intensity of nuclear staining with a classification of 0 (blue), 1+ (yellow), 2+ (orange) and 
3+ (red). Nuclear intensity was calculated from the sum of the product of the % of cells with 
3+ and 2+ scores divided by the sum of the product of % cells with 1+ and 0 scores. Nuclear 
score was calculated as the product of nuclear area (um2) and the nuclear intensity. Archival 
FFPE tissues from breast cancer patients were obtained from the surgical pathology archive 
of the University of Chicago for tissue microarray (TMA) construction. The study was 
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approved by the Institutional Review Boards University of Chicago and East Carolina 
University. Pathological features, including histological diagnosis, grade, tumor size, and 
axillary lymph node metastasis, were abstracted from the pathology report. There were 
survival data on 98 to 100 breast cancer patients from each data set with a median follow-up 
of 8.3 years.
Analysis of Breast Cancer Gene Expression Profiles
Expression patterns of the 1,823 genes identified by CtBP ChIP-Seq were examined in a 
previously published breast cancer containing microarray and patient clinical data set 
available from the University of North Carolina (UNC) which includes 337 human breast 
tumors (UNC337) and is available in the Gene Expression Omnibus (GEO) under accession 
number GEO:(GSE18229) 10. All data sets were median centered within each data set and 
standardized to zero mean and unit variance before downstream analysis 10. ANOVA 
analysis of representative gene expression in tumor samples was determined using the 
UNC337 gene expression dataset. To determine if the overlap of CtBP target gene lists with 
other referenced gene lists, is statistically significant in Venn Diagrams, a hypergeometric 
distribution was calculated to derive the statistical P-value based on 37630 TSSs in refseq 
(HG19, USCS). Analysis of patient survival associated with gene expression from breast 
cancer datasets was performed using BRB ArrayTools Version: 4.1.0 - Beta_3 Release. 
Affymetrix data sets were downloaded from the NCBI Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/). Expression data were loaded into BRB ArrayTools 
using the Data Import Wizard. U133A probe sets for the individual gene signatures were 
identified by using the Affymetrix NetAffx Analysis Center Batch Query tool (http://
www.affymetrix.com/analysis/index.affx). Expression data were filtered to exclude any 
probe set that was not a component of the signatures tested, and to eliminate any probe set 
whose expression variation across the dataset was P>0.05. Kaplan-Meier analysis was 
performed using the Survival Risk Prediction tool, specifying two risk groups, with fitting to 
a Cox proportional hazard model with p-value ≤ 0.05. Distributions of the hazard ratios and 
the logrank test P-values was determined based on 1000 Bootstrap samples where each 
bootstrap sample consists of 50% of cases randomly selected from the whole set 56.
Statistical analysis
All the error bars represent the standard deviations of the mean from at least 3 independent 
biological replicates unless otherwise indicated. Comparison between two groups was done 
using a 2-sided Student’s t test. P-value<0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Global targeting of genome stability and developmental pathways by CtBP differentiation 
(a) Gene ontology analysis indicates that CtBP targets numerous cancer related pathways 
linked to DNA repair, chromatin modifications, cell adhesion and other pathways important 
in developmental processes. (b) ChIP-Seq profiles of the binding of CtBP to selected genes 
that are key genetic drivers of human malignancy including genome stability, epithelial-to-
mesenchymal transition (EMT) and stem cell/tumor initiation cell (TIC) pathways in MCF-7 
cells. Red indicates genes encoded 5′-3′ on the upper strand while green indicates genes 
encoded 5′-3′ on the lower strand. (c) Binding motifs enriched under CtBP ChIP-seq peaks 
revealed by in silico analysis. (d) The large majority of promoter binding sites for CtBP are 
distinct from those bound by LSD1 in MCF-7 and human ES cells.
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Figure 2. CtBP downregulated targets control differentiation and DNA repair
(a) Venn diagrams showing the overlap between CtBP targets and genes down-regulated 
and up-regulated in established EMT and Cancer tumor initiating cell (TIC)/stem cell gene 
signatures. P-values indicate the significance of overlap determined from hypergeometric 
distribution analysis. (b) Unsupervised hierarchical clustering of microarray analysis 
(HGU133plus) of differentially expressed (P<0.05) genes in control and MCF-7 cells 
depleted of CtBP by RNAi. Venn diagram shows the overlap of repressed and induced genes 
with CtBP targets identified by ChIP-seq. (c) Hierarchical clustering of the expression of 
multiple CtBP targets belonging to the gene classes, described in Figure 1, measured by 
quantitative real-time PCR in cells over-expressing CtBP (CtBP) and cells depleted of CtBP 
by RNAi (CtBP KD) compared to GFP control and non-targeting RNAi respectively. 
Bracket indicates CtBP repressed genes that were uniformly upregulated by CtBP depletion 
and repressed by CtBP overexpression. Corresponding expression values with error bars are 
provided in Supplementary Figures S4–S6 (d) Comet assay of MCF-7 cells before and after 
oxidative DNA damage by peroxide treatment and following 2 hour recovery in control cells 
and cells depleted of CtBP by RNAi. (e) Analysis of change in tail moment in control and 
CtBP depleted cells following DNA damage and recovery. The error bars represent the 
standard deviation of the mean from 2 independent experiments. Scale bar = 20 microns.
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Figure 3. CtBP drives acquisition of mesenchymal traits in mammary epithelial cells
(a) Gene expression pattern of CtBP target genes controlling genome stability, EMT and 
Stem cell pathways in MCF-7 cells (top) and MDA-MB-231 cells (bottom) overexpressing 
CtBP or depleted of CtBP by RNAi as indicated. (b) Unsupervised hierarchical clustering 
comparing of the 30 gene validation set expression (see Figure 1b) in cells overexpressing or 
depleted of CtBP. Expression values with error bars are shown in Supplementary Figs. S4–
S5. (c) Promoter Histone H4 acetylation profile (K5, K8, K12) of genes shown in (a) in 
MCF-7 cells (top) and MDA-MB-231 cells (bottom) following CtBP depletion by RNAi. 
Expression values and errors bars including the remaining 30 gene validation set are 
provided in Supplementary Fig S9. (d) E-Cadherin/Vimentin expression ratio in cells 
overexpressing CtBP or depleted of CtBP by RNAi. (e) Wound healing assay shows MCF-7 
control cells and cells overexpressing CtBP1. Vertical line indicates center of wound in the 
scratch assay. White bar, 250 microns. (f) CD44/CD24 expression ratio in MCF-7 and 
MDA-MB-231 cells overexpressing CtBP or depleted of CtBP by RNAi. The error bars 
represent the standard deviation of the mean from 3 independent experiments (a, d, f) or 2 
independent experiments (c). Single asterisk (*) indicates P <0.05) and double asterisk (**) 
indicates P<0.01.
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Figure 4. Calorie restriction decreases CtBP activity and increases DNA repair
(a) CtBP Immuno-histochemical staining of MCF-7 cells grown in high glucose (4.5 g/L) 
and lowglucose (1.0 g/L). Scale bar = 25 microns. Inset is 2 fold magnification. (b) NAD+/
NADH ratio in lysates of MCF-7 cells grown in high and low glucose. (c) Western blot 
analysis of BRCA1 and CtBP2 expression in high and lowglucose treated cells. NPM1 was 
used as loading control. I= insulin. (d) ChIP profile of CtBP binding to the BRCA1 
promoter in cells grown in high glucose versus low glucose as indicated. (e) ChIP profile of 
relative histone 4 lysine acetylation after normalization to ChIP for total histone 4. (f) qRT-
PCR expression of BRCA1 and BRIP1 mRNA in high and low glucose treated cells with and 
without insulin. (g) phospho-gamma H2AX foci profile of cells following ionizing radiation 
at 0, 3 and 6 h. Scale bar = 10 microns. (h) Relative rate of DNA repair expressed as relative 
rate of decrease in foci per cell over time. The error bars represent the standard deviation of 
the mean from 3 independent experiments (b, d, f, h) or 5 independent experiments (e).
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Figure 5. CtBP targets distinguish clinically aggressive subtypes of breast cancer
(a) Unsupervised hierarchical clustering of CtBP target genes in publically available breast 
cancer gene expression studies (UNC337). Highlighted rectangle indicates group of CtBP-
bound genes that are downregulated/repressed preferentially in the basal-like subtype. (b) 
ANOVA profiling of one representative each of the genome stability (BRIP1), EMT 
(GRHL2) and TIC/Stem cell (OVOL2) gene groups, described in Figure 1b, using the 
UNC337 patient gene expression data set. P-values were calculated by comparing mean 
expression across all subtypes. (c) Patients whose tumors differentially express CtBP-bound 
genes show worse clinical outcome (metastasis-free survival) by Kaplan-Meier analysis. 
Patient gene expression data obtained from the Gene Expression Omnibus (GSE11121 and 
GSE2034) were separated into 2 groups based on differential expression CtBP target genes 
(red), and were analyzed by Kaplan Meier analysis. The 95% confidence interval for median 
HR=2.08 is [1.420, 3.070]. The 95% confidence interval for median HR= 2.70 is [1.490, 
5.411]. P-values and hazard ratios (HR) were derived as described in materials and methods.
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Figure 6. Eleveated CtBP protein in patient breast cancers predicts lower median survival
(a) CtBP1 immuno-histochemical staining of normal breast tissue and tissue from triple-
negative breast cancer patients, analyzed for staining intensity using the Aperio nuclear 
algorithm software and then scored for nuclear intensity and nuclear score (weighted by 
nuclear area). Scale bar = 25 microns. (b) Relative survival of a training patient cohort (98) 
scored with low (<100 or <2.0), median (100–300 or 2–5) and high (>300 or > 5) scores for 
CtBP staining analyzed for survival trends by Kaplan-Meier analysis. Median survival for 
all 3 groups are shown. (c) CtBP scoring of a second independent breast cancer patient 
cohort (validation set) showing a similar inverse correlation between CtBP score and median 
survival.
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Figure 7. Small molecule inhibition reverses gene repression by CtBP eviction
(a) Gene expression pattern of CtBP target genes controlling genome stability, EMT and 
Stem cell pathways in MCF-7 cells (left) and MDA-MB-231 cells (right) with and without 
treatment with 10 mM MTOB. (b) Heat map of gene expression of the 30 gene validation 
set (Figure 1b) in MCF-7 (left) and MDA-MB-231 (right) cells treated with and without 
MTOB. Gene expression values and error bars including the remaining 30 genes are 
provided in Supplementary Fig. S13. (c) CtBP qChIP profiles of genome stability, EMT and 
Stem cell pathways genes in MCF-7 (top) and MDA-MB-231 (bottom) cells treated with or 
without MTOB. (d) Heat map of ChIP intensities of 30 gene validation list in MCF-7 and 
MDA-MB-231 cells treated with or without MTOB. Quantitative ChIP values and error bars 
are provided in Supplementary Fig. S14. (e) E-Cadherin/Vimentin ratio in MCF-7 and 
MDA-MB-231 cells treat with and without MTOB. (f) CD44/CD24 ratio in MCF-7 and 
MDA-MB-231 cells treat with and without MTOB.. The error bars represent the standard 
deviation of the mean from 3 independent experiments(a, e, f) or 2 independent 
experiments(c). Single asterisk (*) indicates P <0.05 and double asterisk (**) indicates 
P<0.01.
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Table 1
Genome-wide binding sites for CtBP
Binding Site # Sites
Promoter (<2.5 kB of TSS) 1823
Downstream peaks 916
Distal upstream peaks 1559
Intron 2056
Exon 253
Binding site distribution of CtBP in MCF-7 cells with Z-score ≥ 30. TSS= transcription start site.
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